NovoCure Ltd. (NASDAQ:NVCR) won CE mark for its Optune Pax in adults with locally advanced pancreatic cancer after PANOVA‑3 showed a median OS 16.2 vs 14.2 months (HR 0.82, p=0.039) and longer pain control with mainly mild skin AEs; the company will report Q2 2026 results July 23 before US open and host an 8:00 a.m. EDT call.
Previous Week Recap
- Optune Pax Gets CE Mark: NovoCure’s Optune Pax got CE mark for adults with locally advanced pancreatic cancer. PANOVA‑3 (n=571) showed OS 16.2 vs 14.2 months (HR 0.82, p=0.039); longer pain progression; mainly mild skin AEs.
- NVCR Q2 2026 Results On July 23: NovoCure (NVCR) will report Q2 2026 results July 23 before US open and hold a conference call/webcast at 8:00 a.m. EDT; presentation slides will be posted on its Investor Relations page.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.